breath diagnostic technology · 2020. 8. 10. · teva and ceo of nasvax (tase: nsvx) and immcure...
TRANSCRIPT
Breath Diagnostic Technology
This presentation was prepared by Scent Medical Technologies Ltd. (the “Company”), and is given to you only for the provision of concise information for the sake of convenience, and may not be copied or distributed to any other person. The data and information included in this presentation should not be interpreted as advice and should not be relied on for any purpose. Such data and information should not be copied or used except as expressly permitted in writing. This presentation does not purport to be comprehensive or to contain any and all information that might be relevant in connection with the making of a decision on an investment in securities of the Company nor Nextgen Biomed Ltd (“Nextgen”). No explicit or implicit representation or undertaking is given by any person regarding the accuracy or integrity of any information included in this presentation. No representation or undertaking is given regarding the realization or reasonableness of any forecasts regarding the future chances of the Company nor Nextgen. To obtain a wider picture of the activities of the Company and the risks entailed thereby, see the immediate reports of Nextgen concerning the Company’s recent activities and the Company’s ongoing merger with Nextgen, filed in the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd. websites, including warnings regarding forward-looking information, as defined in the Securities Law, 5728-1968, included therein. The forward-looking information in the presentation may not materialize, in whole or in part, or may materialize differently than expected, or may be affected by factors that cannot be assessed in advance. For the avoidance of doubt, it is clarified that neither the Company nor Nextgen undertakes to update and/or modify the information included in the presentation to reflect events and/or circumstances occurring after the date of preparation of the presentation. This presentation is not an offer nor invitation to buy or subscribe for any securities Nextgen and the Company. This presentation and anything contained herein are not a basis for any contract or undertaking and are not to be relied upon in such context. The information provided in the presentation is not a basis for the making of any investment decision, nor a recommendation or opinion, nor a substitute for the discretion of a potential investor.
Forward Looking Statement
Scentech Medical is a company specializing in Breath Test Diagnostics.
It has been established on the infrastructure of several successful experiments over the last decade, including clinical trials, for the detection of infectious diseases, cancers, and other illnesses by a straightforward test of the patient's breath sample.
Every living organism has unique metabolic processes that produce a particular signature. With the company’s exclusive technology and methodology for identifying "Volatile Organic Compounds" (VOCs) in exhaled breath, we can identify the direct compounds associated with the virus’s activity.
Scentech Medical Knowledge and Experience
Our technology detects the presence of unique metabolic processes that are associated with pathogens. Each pathogen has a different genetic expression, which creates a unique metabolic fingerprint. This enables our Rapid Scent Test (RST) to identify various diseases, even in the early stages of infection, when patients may be asymptomatic.
IP
Scentech Medical has a broad IP portfolio and trade secrets. Recently, the company filed a unique breakthrough patent for the detection of various types of cancer, tuberculosis (TB), and continuous monitoring of the effectiveness of the selected treatment for the disease.
Developing a Digital Test Using Exhalation Technology for Rapid Virus Detection
Pandemic Risks - We Discovered the World is not Safe
Coronavirus Cases:
10,694,288Deaths:
516,210Estimated Expense:
Over $2 Trillion
* The displayed data is updated to 2/7/2020
• The world was not prepared
• There is currently no vaccine
• The virus is mutating, creating many new strains
• Existing tests are expensive, inaccurate, and inefficient
The COVID-19 pandemic exposed one of the main weaknesses of the 21st century’s globalization
“worldwide pandemic risks”
The Solution
Biological Security in Borders
The World Needs a Test that Offers
Constant UpdatesUpdates for virus mutations or new
future viruses
SpeedVirus detection within
seconds with on-the-
spot results
AccuracyGreater than 90% accurate
Early DetectionDetection of asymptomatic
patients
* All Pictures shown are for illustration purpose only
Approximate Costs
$150K - $400K per device
$5-10 per test
Approximate Dimensions
Length: 1M / Width: 1.48M
Device Operation:
One operator with no technical skills required
Approximate mapping
in the next 6 weeks
Approximate Outputs
840 tests per day
(if operated 14 hours a day)
Our Product: RBT – Rapid Breath Test Virus Breathalyzer: An efficient, accurate, real time Point of Care test
Approximate Supply date
October 2020
Scentech Medical will provide access for other breath test devices to the
Scentech Medical Cloud Database of biomarkers and create a Great Network Effect
Cloud Database of Metabolic “Fingerprints”
https://www.youtube.com/watch?v=9rGian6PWqQ&feature=youtu.beLink to the video:
Mapping stages of the virus’ “fingerprint” via clinical trials
The company has started two clinical experiments in parallel and is planning another one soon to map the virus’s biomarkers. The mapping process is estimated to take six weeks
Status Update
Major Market Potential
Borders – a potential charging $1 per test per passenger adds up quickly to$25 billion in market potential
Public event location - charging 50 cents per test of patrons entering sports events or performances translates tomore than a billion dollar market potential
Medical centres -with the sale of dedicated devices at less than $1,000 per device to clinics and doctors worldwide, a potential market of over $8 billion will open up
Estimated Roadmap Commercialization within 24 months
Reverse merger into public company
3
1st prototype for Corona breathalyser
First operational Corona breathalyserfor identifying coronavirus in the field
18
Launch of 2nd
generation breathalyser
Define first coronavirus VOCs “Fingerprint” at Meir Medical Center
2
Post-marketing validation
4 12 24
1
-A Round
Clinical Studies & Hardware Development:
A+ Round B Round
5-7
6
month
months
months
months
months months
months months months
Validation Cross-section clinical trial with the Israeli Defense Forces
JV establishment with a big medical devices company
Scentech Medical in the Media
https://www.ynet.co.il/articles/0,7340,L-5717024,00.html
https://www.youtube.com/watch?v=EccjQtJXPxE&t=23s
https://www.calcalist.co.il/markets/articles/0,7340,L-3807836,00.html https://www.globes.co.il/news/article.aspx?did=1001325335 http://www.israelnationalnews.com/News/Flash.aspx/496267
Link to the video:
New developmentA Breathalyzer that detects whether you have the Coronavirus
The Team
Dr. Eliaz is Founder and Managing Director at ElromVentures. Rom was Managing Director and aMoon Fund, the Head of Merck ventures’ Fund and Bio-Incubator in Israel ,VP of Innovative Branded Products at Teva and CEO of NasVax (TASE: NSVX) and ImmcureTherapeutics, VP of Product Development at, Intradigm(acquired by Silence Therapeutics), RinatNeuroscience (acquired by Pfizer) and Alza (acquired by J&J).Rom received his PhD (cum-laude) chemical engineering and Biotechnology from the Weizmann Institute and Ben-Gurion University (BGU) and MBA from Harvard and Boston University joint program at BGU.
Yaniv combines extensive financial expertise with significant experience in accelerating company growth. He was the Chief Strategy Officer at Excellence Investment House, where he managed over 35 billion dollars in assets. Yaniv is an NFX Alumnus and has an MA in Economics from Tel Aviv University.
Dr. Rom Eliaz
Executive Board Member
Yaniv Chevron
Chief Executive Officer
Drew is a seasoned expert in the areas of metabolomics, breath analysis, and genetic expression diagnostics. He served on multiple advisory panels addressing the planning for pandemics and global health threats. He continues to be an outspoken advocate for the need for rapid diagnostic tools based on genetic expression, as a means to contain the spread of infectious diseases and improve health outcomes.
Drew Morris
Chief Research Officer
Specialist in General and Urological Surgery In the past, he managed the organ transplant unit at Sheba Medical Center. He is a graduate of the FDA standard GMP examiners and was certified in Health Systems Management, at the Heller School, University of Brandeis, Boston, USA. Additionally, Dr.Cantor has served as the Head of Quality and Technology Administration in the USSR and as Head of the TechnionRisk Management Training Village in Haifa. He founded and has served as the Head of the Medical Policy Division of the Medical Association in Israel.
Dr. Amar earned her Ph.D. at the Faculty of Life Science, Bar-Ilan University, and completed post-doctoral studies at the Lautenberg Center for Immunology and Cancer Research at the Faculty of Medicine, Hebrew University, Jerusalem. Further, she holds a BSc and MSc from the Faculty of Biology at the TechnionIsrael Institute of Technology, as well as an MA in Law from Bar-Ilan University. Since graduating, she has held a number of management positions in the Biomed and Pharma Industries. Most recently, as CEO of ShizimXLmedical devices accelerator and Chief of Business Development at Alvit Pharma.
Regina brings her drive and passion for science to her role as the Analytical Laboratory Manager. She holds a PhD in Materials Chemistry from the University of Alberta and a BSc in Chemistry and Computer Science from Western University. Regina honed her analytical skills as a researcher at the Analytical Laboratory of the Israeli Air Force, where she specialized in the identification and method development for the analysis of non-metal materials used in the aviation industry.
Dr. Keren-Or Amar
Healthcare Business Consultant
Dr. Regina Sinelnikov
Analytical Lab Manager
Dr. Udi Cantor
Chief Medical Officer